Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus

Next Previous
X
Search
Trial Profile

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cadisegliatin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SimpliciT1
  • Sponsors vTv Therapeutics LLC

    • Most Recent Events

    • 13 Apr 2021 According to a vTv Therapeutics media release, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes. It was supported by the recent positive results from this study.
    • 12 Apr 2021 According to a vTv Therapeutics media release, Dr. Klara Klein, MD, PhD (Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill) is the Sub-Principal Investigator of this study.
    • 12 Apr 2021 Results presented in a vTv Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top